Therapeutic inhibition of ferroptosis in neurodegenerative disease. - Université de Lille Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Trends in Pharmacological Sciences Année : 2023

Therapeutic inhibition of ferroptosis in neurodegenerative disease.

Sean K. Ryan
  • Fonction : Auteur
Cathryn L. Ugalde
  • Fonction : Auteur
John Skidmore
  • Fonction : Auteur
Timothy R. Hammond
  • Fonction : Auteur


Iron accumulation has been associated with the etiology and progression of multiple neurodegenerative diseases (NDDs). The exact role of iron in these diseases is not fully understood, but an iron-dependent form of regulated cell death called ferroptosis could be key. Although there is substantial preclinical and clinical evidence that ferroptosis plays a role in NDD, there are still questions regarding how to target ferroptosis therapeutically, including which proteins to target, identification of clinically relevant biomarkers, and which patients might benefit most. Clinical trials of iron- and ferroptosis-targeted therapies are beginning to provide some answers, but there is growing interest in developing new ferroptosis inhibitors. We describe newly identified ferroptosis targets, opportunities, and challenges in NDD, as well as key considerations for progressing new therapeutics to the clinic.
Fichier non déposé

Dates et versions

hal-04597764 , version 1 (03-06-2024)



Sean K. Ryan, Cathryn L. Ugalde, Anne-Sophie Rolland, John Skidmore, David Devos, et al.. Therapeutic inhibition of ferroptosis in neurodegenerative disease.. Trends in Pharmacological Sciences, 2023, Trends in Pharmacological Sciences, 44, pp.674-688. ⟨10.1016/⟩. ⟨hal-04597764⟩


0 Consultations
0 Téléchargements



Gmail Mastodon Facebook X LinkedIn More